These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 33380605)

  • 1. A buprenorphine-naloxone induction in the North.
    Jones MK; Quinn M
    Can J Rural Med; 2021; 26(1):35-37. PubMed ID: 33380605
    [No Abstract]   [Full Text] [Related]  

  • 2. Buprenorphine-naloxone.
    Hu T; Nijmeh L; Pyle A
    CMAJ; 2018 Nov; 190(47):E1389. PubMed ID: 30478217
    [No Abstract]   [Full Text] [Related]  

  • 3. [Not Available].
    Marwah R; Coons C; Myers J; Dumont Z
    Can Fam Physician; 2020 Dec; 66(12):891-894. PubMed ID: 33334955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series.
    Klaire S; Zivanovic R; Barbic SP; Sandhu R; Mathew N; Azar P
    Am J Addict; 2019 Jul; 28(4):262-265. PubMed ID: 30901127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose buprenorphine for treatment of high potency opioid use disorder.
    Danilewitz M; McLean M
    Drug Alcohol Rev; 2020 Feb; 39(2):135-137. PubMed ID: 31769109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone.
    Antoine D; Huhn AS; Strain EC; Turner G; Jardot J; Hammond AS; Dunn KE
    Am J Addict; 2021 Jan; 30(1):83-87. PubMed ID: 32572978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
    Srivastava A; Kahan M; Nader M
    Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine Microdose Induction for the Management of Prescription Opioid Dependence.
    Robbins JL; Englander H; Gregg J
    J Am Board Fam Med; 2021 Feb; 34(Suppl):S141-S146. PubMed ID: 33622829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methadone to buprenorphine/naloxone induction without withdrawal utilizing transdermal fentanyl bridge in an inpatient setting-Azar method.
    Azar P; Nikoo M; Miles I
    Am J Addict; 2018 Dec; 27(8):601-604. PubMed ID: 30387894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why is buprenorphine coformulated with naloxone?
    Urnoski E
    JAAPA; 2017 Nov; 30(11):44-45. PubMed ID: 29064938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case of Opioid Overdose and Subsequent Death After Medically Supervised Withdrawal: The Problematic Role of Rapid Tapers for Opioid Use Disorder.
    Chang DC; Klimas J; Wood E; Fairbairn N
    J Addict Med; 2018; 12(1):80-83. PubMed ID: 28930773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A New Formulation of Buprenorphine/Naloxone.
    J Addict Nurs; 2015; 26(2):104-5. PubMed ID: 26053085
    [No Abstract]   [Full Text] [Related]  

  • 14. A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder.
    Wilson CG; Ramage M; Fagan EB
    J Rural Health; 2021 Jan; 37(1):169-171. PubMed ID: 32277732
    [No Abstract]   [Full Text] [Related]  

  • 15. Are the Patients Ready for the Change?: An Empirical Study to Evaluate the Impact of Change in Formulation of Buprenorphine-Naloxone on Prescription Pattern, Treatment Adherence, and Patient Satisfaction.
    Balhara YPS; Singh S; Sarkar S
    Subst Use Misuse; 2019; 54(2):307-314. PubMed ID: 30513249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Case Report: Rapid Micro-Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended-Release in an Adolescent With Severe Opioid Use Disorder.
    Azar P; Wong JSH; Jassemi S; Moore E; Vo DX; Nikoo M; Young S
    Am J Addict; 2020 Nov; 29(6):531-535. PubMed ID: 32346944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buprenorphine-Naloxone Treatment in Physicians and Nurses With Opioid Dependence.
    Braquehais MD; Fadeuilhe C; Håkansson A; Bel MJ; Navarro MC; Roncero C; Bruguera E; Casas M
    Subst Abus; 2015; 36(2):138-40. PubMed ID: 25738533
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of Kratom Withdrawal and Addiction With Buprenorphine.
    Khazaeli A; Jerry JM; Vazirian M
    J Addict Med; 2018; 12(6):493-495. PubMed ID: 30383616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sublingual buprenorphine-naloxone precipitated withdrawal-A case report with review of literature and clinical considerations.
    Bhatia G; Sarkar S
    Asian J Psychiatr; 2020 Oct; 53():102121. PubMed ID: 32460142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of chronic pain and opioid dependence with buprenorphine/naloxone.
    Chang HM; Chen LY
    Psychiatry Clin Neurosci; 2018 Jun; 72(6):454. PubMed ID: 29573109
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.